Physician profile
Nathan P Hite
NPI 1609175348
$9,082.00
in general payments reported to CMS, 2019-2025
27 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,424 · 2020: $207 · 2021: $3,258 · 2022: $167 · 2023: $2,236 · 2024: $517 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931 · Travel and Lodging: $1,080 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.55 |
| Travel and Lodging | $1,079.90 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,562.80 | 2019-2023 | Da Vinci Surgical System |
| Baxter Healthcare | $437.50 | 2020-2024 | Seprafilm |
| Medtronic, INC. | $380.96 | 2022-2025 | Interstim, Signia, Sonicision |
| Takeda Pharmaceuticals U.S.A., INC. | $266.37 | 2021-2025 | Gattex |
| Kerecis Limited | $209.10 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Pacira Pharmaceuticals Incorporated | $165.59 | 2020-2025 | Exparel |
| Braintree Laboratories, INC. | $148.67 | 2019-2024 | Sutab, Suflave |
| Stryker Corporation | $141.56 | 2019 | |
| Kci USA, INC. | $128.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.04 | 2019-2020 | |
| Davol INC. | $80.43 | 2024 | Arista Ah Flexitip |
| Boston Scientific Corporation | $59.57 | 2024 | |
| Smith+Nephew, INC. | $53.94 | 2019-2025 | Renasys Touch |
| Innovation Technologies INC | $45.60 | 2024-2025 | Irrisept |
| Merck Sharp & Dohme LLC | $41.20 | 2023 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $37.41 | 2022-2023 | Myrisk |
| Lsi Solutions INC | $29.34 | 2021 | |
| Sanara Medtech INC. | $27.98 | 2023 | Celleraterx |
| Ethicon US, LLC | $27.95 | 2021 | |
| Heron Therapeutics, INC. | $24.00 | 2025 | Zynrelef |
| Exact Sciences Corporation | $22.78 | 2025 | Cologuard Collection Kit |
| Convatec INC. | $19.33 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.46 | 2023 | Rebyota |
| Shire North American Group INC | $17.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.10 | 2020 | |
| Axonics, INC. | $14.64 | 2023 | Bulkamid |
| Medtronic USA, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.